重药控股股份有限公司 市值管理制度 第一章 总则 第一条 为加强重药控股股份有限公司（以下简称"公司"）市值管理工作， 进一步规范公司市值管理行为，切实保护公司投资者特别是社会公众投资者的合 法权益，树立公司诚信形象，提高公司核心竞争力，实现公司价值最大化和股东 利益最大化，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证 券交易所股票上市规则》《重药控股股份有限公司章程》（以下简称"《公司章程》"） 及其他法律、行政法规和规章的有关规定，结合本公司实际情况，制定本制度。 第二条 市值管理，即公司以提高上市公司质量为基础，为提升投资者回报 能力和水平而实施的战略管理行为。公司通过制定合适的发展战略、完善公司治 理、改进经营管理、培育核心竞争力，以及通过资本运作工具实现公司市值与内 在价值的动态均衡，在公司治理、日常经营、并购重组及融资等重大事项决策中 充分考虑投资者利益和回报，坚持稳健经营，避免盲目扩张，不断提升上市公司 投资价值。 第二章 市值管理的基本原则 第三条 市值管理的基本原则 （一）合规性原则：公司市值管理工作应当在严格遵守相关法律、行政法规、 规章、规范性文件、行业规范、自律规则、公 ...

二、聘任总会计师情况 公司于 2025 年 6 月 13 日召开第九届董事会第十四次会议，审议通过了《关 于聘任公司总会计师的议案》。根据《公司法》等相关法律法规及《公司章程》 的规定，经公司总经理提名，并经董事会提名委员会及审计委员会审核通过，董 事会同意聘任杨磊先生为公司总会计师（简历详见附件），任期自董事会审议通 过之日起至第九届董事会届满之日止。 证券代码：000950 证券简称：重药控股 公告编号：2025-038 重药控股股份有限公司 关于财务总监辞职暨聘任总会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、财务总监辞职情况 重药控股股份有限公司（以下简称"公司"）董事会于 2025 年 6 月 13 日收 到公司财务总监邱天先生的书面辞职报告。邱天先生因工作调整原因，申请辞去 公司财务总监职务，辞职后仍在公司任董事会秘书职务。邱天先生原定任期至第 九届董事会任期届满（2026 年 11 月 29 日），其辞职不会影响公司相关工作的 正常运作。根据《公司法》《公司章程》等相关规定，其辞职报告自送达董事会 时生效。 截至本公告披露日， ...

证券代码：000950 证券简称：重药控股 公告编号：2025-037 重药控股股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第九届董事会第十四次会议于 2025年6月13日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2025年6月9日以电子邮件和电话通知方式发出。会议应出席董事11人，实际出席 会议的董事11人。会议由公司董事长袁泉主持。本次会议的召开符合《公司法》、 《公司章程》的有关规定。 （一）审议通过《关于聘任公司总会计师的议案》 具体内容详见同日披露的《关于财务总监辞职暨聘任总会计师的公告》。 表决结果：同意11票，反对0票，弃权0票。 本议案经审计委员会、提名委员会审议通过。 （二）审议通过《关于制定<市值管理制度>的议案》 具体内容详见同日披露的《市值管理制度》。 表决结果：同意11票，反对0票，弃权0票。 三、备查文件 第九届董事会第十四次会议决议 特此公告 重药控股股份有限公司董事会 二、董事会会议审议情况 202 ...

Core Viewpoint - The botulinum toxin industry in China is experiencing rapid growth, with the market size projected to increase from 1.9 billion yuan in 2017 to 9.9 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 26.6% [1][13]. Industry Overview - Botulinum toxin, originally used for treating muscle spasms, has become a popular choice in medical aesthetics due to its minimal invasiveness and quick recovery time [3][13]. - The application range of botulinum toxin is expanding beyond traditional uses like wrinkle reduction and facial slimming to include treatments for conditions such as migraines and muscle tension disorders [1][13]. Market Dynamics - The medical aesthetics market in China is projected to reach 288 billion yuan by 2024, with a year-on-year increase of 8.03%, indicating a growing consumer demand for beauty enhancement services [11][13]. - The market is characterized by a "six-way split" among leading products, with brands like Botox, Hengli, and Letyb gaining significant market shares [15][17]. Competitive Landscape - The botulinum toxin market is competitive, with established companies like Fosun Pharma, Haohai Biological Technology, and Lanzhou Biological Products Research Institute leading the industry [17][18]. - New entrants are emerging, leveraging innovative technologies and marketing strategies to capture market share [17]. Development Trends 1. **Increasing Industry Penetration** - As living standards rise, the penetration rate of medical aesthetics is expected to increase, particularly in lower-tier cities and rural areas, driven by a younger consumer base [23]. 2. **Enhanced Regulatory Oversight** - The government is intensifying regulations on botulinum toxin production and distribution to ensure safety and quality, which will promote the healthy development of the market [24]. 3. **Rise of Recombinant Botulinum Toxin** - Recombinant botulinum toxin is anticipated to become a future trend due to its lower biological risks, higher purity, and production efficiency, addressing limitations of traditional products [25].

Group 1 - The company has approved a profit distribution plan for the year 2024, proposing a cash dividend of 0.30 RMB per 10 shares, totaling approximately 51.85 million RMB [1][2] - The total share capital as of December 31, 2024, is 1,728,184,696 shares, and the distribution will be adjusted if there are changes in the total share capital before implementation [1][2] - The dividend will be distributed to all shareholders registered by June 19, 2025, with the ex-dividend date set for June 20, 2025 [2] Group 2 - The cash dividend will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [2] - Different tax rates will apply for various categories of shareholders, with specific provisions for Hong Kong investors and domestic investors [1][2] - The company has provided contact information for inquiries regarding the dividend distribution [2]

证券代码：000950 证券简称：重药控股 公告编号：2025-036 重药控股股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东会审议通过利润分配方案的情况 1.公司于 2025 年 5 月 14 日召开 2024 年年度股东会审议通过了《2024 年度 利润分配预案》，2024 年度利润分配方案的具体内容为：以 2024 年 12 月 31 日 的总股本 1,728,184,696 股为基数，向全体股东每 10 股派发 0.30 元人民币现金 （含税），分配总金额为 51,845,540.88 元。不送红股，不以公积金转增股本。若 在分配预案实施前公司总股本由于可转债转股、股份回购、股权激励、再融资新 增股份上市等原因而发生变化的，将按每股分配金额不变的原则相应调整分配总 额。 2.自分配方案披露至实施期间，公司股本总额未发生变化。 3.本次实施的分配方案与股东会审议通过的分配方案一致。 4.本次分配方案实施时间距离股东会审议通过之日起未超过两个月。 二、本次实施的利润分配方案 本公司 2024 年年度权 ...

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue growth of 17% in medical devices and 10% in professional pharmacy (DTP) sales [2] - The total revenue from the traditional Chinese medicine sector reached 14.86 billion CNY in 2024, with over 140 subsidiaries involved in this business [5] Group 2: Strategic Developments - The company has established partnerships with over 400 medical institutions under the General Group, opening accounts in 102 of them, including 86 grade hospitals [2] - The "300 Cities" strategic plan has been implemented, covering 160 cities across 31 provinces and regions in China [4] Group 3: Future Plans - The company aims to deepen its investment and acquisition efforts in 2025 to strengthen its regional network and enhance competitive advantages [4] - Future developments in the traditional Chinese medicine sector will focus on building a comprehensive industry chain, including smart Chinese medicine pharmacies and specialty Chinese medicine pieces [5] Group 4: Marketing and Sales Initiatives - The company has formed a national marketing team to enhance service capabilities, achieving sales in 31 provinces through its CSO projects [6] - New product promotions have been successfully launched, including several proprietary drugs [6]

Core Viewpoint - The article highlights the emergence of a notable individual investor, Zhang Sufen, in the A-share market, who has made significant investments in multiple listed companies, positioning herself among the top shareholders of 15 companies as of the first quarter of 2025 [1][2][3]. Group 1: Investment Profile - Zhang Sufen holds substantial shares in various companies, with a total holding of 349.66 million shares across 15 listed companies, making her the second-largest shareholder in Electronic City and the fourth-largest in Shaanxi Guotou A [3][4]. - Her investment strategy appears to focus on low-priced stocks, with most of her holdings priced below 10 yuan, indicating a preference for undervalued assets [7][8]. - The total market value of her holdings exceeds 1.38 billion yuan, with five stocks valued over 100 million yuan each [8]. Group 2: Performance and Strategy - Zhang's investments have shown mixed results, with the highest floating profit being 26.81% from Liugang Co., while the largest loss is 13.62% from Shaanxi Construction [3][4]. - She has demonstrated a long-term investment approach, often increasing her holdings over several quarters, as seen in her continuous accumulation of shares in low-performing stocks like New Star Foundry [6][7]. - Despite her success, she has also faced significant losses, such as a 30% loss in Yibai Pharmaceutical, highlighting the risks associated with her investment choices [8][9]. Group 3: Market Impact and Perception - Zhang Sufen's investment activities have drawn attention in the market, with speculation about her potential connections to larger investment networks, suggesting that her strategies may not be typical of individual investors [7][8]. - Her approach to investing, characterized by a focus on low-priced stocks and a willingness to endure volatility, positions her as a unique figure in the A-share market, comparable to institutional investors [6][7].

Group 1: Company Overview and Performance - The company operates in the pharmaceutical distribution industry, focusing on pharmaceutical commerce, warehousing, logistics, and R&D, with a marketing network covering the entire country [2] - In Q1 2025, the company achieved revenue and net profit growth, with medical devices and specialty pharmacy sales increasing by 17% and 10% year-on-year, respectively [2] - As of the end of 2024, revenue from narcotic and psychotropic products accounted for 3.75% of total income [3] Group 2: Collaboration and Market Expansion - The company is one of the national wholesale enterprises for narcotic drugs, with a sales network covering all 31 provinces, municipalities, and autonomous regions [3] - The company has accelerated collaboration with over 400 medical institutions under the China General Technology Group, having opened 102 accounts in 21 provinces, including 86 grade hospitals [4] Group 3: Strategic Responses to Market Challenges - In response to price reductions from centralized procurement and medical insurance cost control, the company aims to optimize its industrial layout and explore high-growth niche markets [5] - The company is implementing a "Five Armies" strategic plan to enhance profitability through five segments: pharmaceutical sales, medical devices, specialty pharmacies, traditional Chinese medicine, and emerging businesses [5] - Since entering the central enterprise system, the company has improved its credit and financing channels, leading to a noticeable decline in financing costs since 2024 [5] Group 4: Future Plans and Investments - The company plans to actively promote nationwide commercial network coverage under the "300 Cities" strategic plan, leveraging its scale, network, and service advantages for acquisitions and strategic partnerships in medical devices and traditional Chinese medicine [6]

Group 1 - Chongqing Pharmaceutical Holdings received a warning letter from the Chongqing Securities Regulatory Bureau due to issues with revenue recognition in 2023, leading to inaccurate financial disclosures [1] - The company has implemented multiple corrective measures and aims to enhance its financial accounting and internal control governance [1] - This incident reflects deficiencies in the company's financial management and disclosure practices, which may impact market confidence in the short term [1] Group 2 - Lu Kang Pharmaceutical responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about land reserve income recognition and accounts receivable [2] - The company emphasized that its main distributors are closely related to its core business and that there are no abnormal sales activities [2] - This response demonstrates the company's commitment to regulatory compliance and transparency, which may bolster investor confidence [2] Group 3 - BeiGene plans to change its registered location from the Cayman Islands to Switzerland and will issue 133 million new shares to its wholly-owned subsidiary [3] - This move reflects the company's internationalization strategy and ongoing commitment to its equity incentive plan [3] - The actions taken are expected to enhance the company's long-term value and competitiveness in the global market [3] Group 4 - Merck China announced the cancellation of temporary surcharges on orders to China in response to the US-China agreement to suspend tariff increases for 90 days [4] - This decision is aimed at stabilizing customer relationships in the Chinese market and reducing operational costs [4] - The move highlights the sensitivity of global pharmaceutical companies to trade policy changes and their strategic adjustments in response [4] Group 5 - Meinian Health reported progress in acquiring partial equity in thirteen companies, including Yunnan Ciming Health Service Co., Ltd. [6] - The completion of business registration changes for two subsidiaries marks a significant step in the acquisition process [6] - This acquisition is part of the company's strategic plan to expand market share and strengthen its competitive position in the health examination industry [6]